# Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

> **NCT00427791** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Etoposide
- **RADIATION:** Total Body Irradiation
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00427791
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427791, "Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00427791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*